(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
0.54% INR 6 252.10
Live Chart Being Loaded With Signals
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments...
Stats | |
---|---|
Šios dienos apimtis | 412 540 |
Vidutinė apimtis | 384 166 |
Rinkos kapitalizacija | 1 041.06B |
EPS | INR0 ( 2024-01-29 ) |
Kita pelno data | ( INR73.29 ) 2024-05-06 |
Last Dividend | INR40.00 ( 2023-07-11 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 19.95 |
ATR14 | INR5.92 (0.09%) |
Tūris Koreliacija
Dr. Reddy's Laboratories Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
SETF10GILT.NS | 0.933 |
ASHIANA.NS | 0.919 |
MOGSEC.NS | 0.915 |
ADORWELD.NS | 0.905 |
BHARATWIRE.NS | 0.903 |
IZMO.NS | 0.898 |
BAJAJ-AUTO.NS | 0.893 |
GTNTEX.NS | 0.884 |
CYIENT.NS | 0.883 |
MASPTOP50.NS | 0.882 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
STARTECK.NS | -0.898 |
SUNCLAYLTD.NS | -0.875 |
SCI.NS | -0.87 |
TEAMLEASE.NS | -0.856 |
ORTINLAB.NS | -0.853 |
MOHOTAIND.NS | -0.851 |
EASTSILK.NS | -0.851 |
ROLTA.NS | -0.844 |
CLNINDIA.NS | -0.844 |
GENESYS.NS | -0.839 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Dr. Reddy's Laboratories Koreliacija - Valiuta/Žaliavos
Dr. Reddy's Laboratories Finansinės ataskaitos
Annual | 2022 |
Pajamos: | INR245.88B |
Bruto pelnas: | INR169.30B (68.86 %) |
EPS: | INR271.43 |
FY | 2022 |
Pajamos: | INR245.88B |
Bruto pelnas: | INR169.30B (68.86 %) |
EPS: | INR271.43 |
FY | 2022 |
Pajamos: | INR214.39B |
Bruto pelnas: | INR113.84B (53.10 %) |
EPS: | INR142.08 |
FY | 2021 |
Pajamos: | INR189.72B |
Bruto pelnas: | INR103.08B (54.33 %) |
EPS: | INR103.94 |
Financial Reports:
No articles found.
Dr. Reddy's Laboratories Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR60.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR40.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR2.50 | 2003-08-08 |
Last Dividend | INR40.00 | 2023-07-11 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | INR363.00 | -- |
Avg. Dividend % Per Year | 0.62% | -- |
Score | 3.63 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.28 | |
Div. Directional Score | 8.85 | -- |
Year | Amount | Yield |
---|---|---|
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR40.00 | 1.93% |
2019 | INR20.00 | 0.77% |
2020 | INR25.00 | 0.87% |
2021 | INR25.00 | 0.48% |
2022 | INR60.00 | 1.24% |
2023 | INR40.00 | 0.94% |
2024 | INR0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TVSSRICHAK.NS | Dividend Junior | 2023-09-04 | Annually | 18 | 0.72% | |
PNCINFRA.NS | Dividend Junior | 2023-09-22 | Annually | 10 | 0.13% | |
JMFINANCIL.NS | Dividend Junior | 2023-05-19 | Annually | 18 | 1.09% | |
DIXON.NS | Dividend Knight | 2023-09-22 | Annually | 7 | 0.04% | |
63MOONS.NS | Dividend Junior | 2023-09-20 | Annually | 20 | 0.75% | |
SONATSOFTW.NS | Dividend Knight | 2023-07-21 | Semi-Annually | 23 | 1.92% | |
MOLDTECH.NS | Dividend Junior | 2023-09-18 | Annually | 9 | 1.62% | |
HEG.NS | Dividend Junior | 2023-08-24 | Annually | 23 | 1.70% | |
BHARATRAS.NS | Dividend Junior | 2023-09-06 | Annually | 17 | 0.01% | |
RAMAPHO.NS | No Dividend Player | 2023-08-10 | Annually | 3 | 0.17% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.192 | 1.500 | 6.15 | 9.23 | [0 - 0.5] |
returnOnAssetsTTM | 0.140 | 1.200 | 5.33 | 6.40 | [0 - 0.3] |
returnOnEquityTTM | 0.209 | 1.500 | 8.79 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.127 | -1.000 | 8.73 | -8.73 | [0 - 1] |
currentRatioTTM | 2.55 | 0.800 | 2.26 | 1.809 | [1 - 3] |
quickRatioTTM | 1.800 | 0.800 | 4.12 | 3.30 | [0.8 - 2.5] |
cashRatioTTM | 0.0784 | 1.500 | -0.675 | -1.013 | [0.2 - 2] |
debtRatioTTM | 0.0532 | -1.500 | 9.11 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 44.26 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 321.84 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 172.31 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0741 | -1.500 | 9.70 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.641 | 1.000 | 2.66 | 2.66 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.240 | 1.000 | 7.20 | 7.20 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.70 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.728 | 0.800 | 8.48 | 6.79 | [0.5 - 2] |
Total Score | 11.41 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 19.94 | 1.000 | 8.09 | 0 | [1 - 100] |
returnOnEquityTTM | 0.209 | 2.50 | 9.22 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 172.31 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.640 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 321.84 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.127 | 1.500 | 8.73 | -8.73 | [0 - 1] |
pegRatioTTM | 0.219 | 1.500 | -1.873 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.198 | 1.000 | 7.56 | 0 | [0.1 - 0.5] |
Total Score | 6.28 |
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.